Circulating vascular endothelial growth factor and interferon-γ- inducible protein-10 levels in pancreatic cancer during chemotherapy

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3287-3291

  Bellone, Graziella ^a,c   Novarino, Anna ^b   Chiappino, Isabella ^b   Gramigni, Claudia ^a   Carbone, Anna ^a   Addeo, Alfredo ^b   Tonel, Elena ^a   Bertetto, Oscar ^b   Emanuelli, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Department of Clinical Physiopathology ^*  (Italy)

Author keywords

5 fluorouracil; Gemcitabine; IP 10; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic carcinoma; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOKINES, CXC; CROSS-OVER STUDIES; DEOXYCYTIDINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUOROURACIL; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23344438469     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
2. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
3. Folberg R and Maniotis AJ: Vasculogenic mimicry. APMIS 112: 508-525, 2004.
4. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
5. Mattern J, Koomagi R and Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73: 931-934, 1996.
6. Yoshiji H, Gomez DE, Shibuya M and Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56: 2013-2016, 1996.
7. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF and Senger DR: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735, 1993.
8. Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF and Ramakrishnan S: Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121: 169-175, 1997.
9. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N and Nakamura M: Vascular endothelial growth factor (VEGF) endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77: 998-1002, 1998.
10. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.) 362: 841-844, 1993.
11. Rollins BJ: Chemokines. Blood 90: 909-928, 1998.
12. Strieter RM, Belperio JA, Phillips RJ and Keane MP: CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14: 195-200, 2004.
13. Neville LF, Mathiak G and Bagasra O: The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8: 207-219, 1997.
14. Arenberg DA, White ES, Burdick MD, Strom SR and Strieter RM: Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10). Cancer Immunol Immunother 50: 533-538, 2001.
15. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI and Strieter RM: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184: 981-992, 1996.
16. Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM and Alexander HR: Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 99: 149-53, 2002.
17. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G and Campani D: Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57: 630-636, 2004.
18. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A and Post S: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25: 122-129, 2002.
19. Klauber N, Parangi S, Flynn E, Hamel E and D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997.
20. Hirata S, Matsubara T, Saura R, Tateishi H and Hirohata K: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 32: 1065-1073, 1989.
21. Steiner R: Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. EXS 61: 449-454, 1992.
22. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
23. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E and de Gramont A: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543-4548, 2002.
24. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME and Norman AR: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 15: 64-69, 2004.
25. Rothenberg ML, Oza AM, Bigelow RH, Berlin ID, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N and Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003.
26. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ack and SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
27. Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E and Rougier P: Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 15: 467-473, 2004.
28. Pizzolato IF and Saltz LB: Irinotecan (Campto) in the treatment of pancreatic cancer. Expert Rev Anticancer Ther 3: 587-593, 2003.
29. Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F and Del Tacca M: Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol 498: 2787-2790, 2004.
30. Poon RT, Fan ST and Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19: 1207-1225, 2001.
31. O'Reilly MS, Holmgren L, Chen C and Folkman J: Angiostatin induces and sustains dormancy of human primary tumor in mice. Nat Med 2: 689-692, 1996.
32. Drevs J, Fakier J, Eisele S, Medinger M, Bing G, Esser N, Marme D and Unger C: Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24: 1759-1763, 2004.
33. Pohle T, Becker JC, Markmann A, Lugering N, Pauels HG, Konturek JW and Domschke W: Aspirin effects on gastric epithelial cell proliferation and cytokine expression. Microsc Res Tech 53: 354-359, 2001.
34. Roy S, Balasubramanian S, Wang J, Chandrashekhar Y, Charboneau R and Barke R: Morphine inhibits VEGF expression in myocardial ischemia. Surgery 134: 336-344, 2003.